Aclaris Therapeutics Receives FDA Fast Track for Modzatinib
WAYNE, Pa., August 6, 2026 Aclaris Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Phase 2b trial
Advertisement
Evommune Launches Phase 2b Trial of EVO756 for Migraine Prevention
PALO ALTO, Calif., & NEW YORK, July 30, 2026 Evommune announced that the first patient has been dosed in...
CalciMedica Aligns With FDA on Auxora Phase 2b Trial
LA JOLLA, Calif., July 29, 2026 CalciMedica, Inc. has announced a significant regulatory milestone after reaching alignment with the...
Medicus Pharma Receives FDA Clearance for Registrational SkinJect Study
PHILADELPHIA, July 27, 2026 Medicus Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has issued a...
Kinaset Doses First Patient in Phase 2b Frevecitinib Trial
BOSTON, MA, July 20, 2026 Kinaset Therapeutics announced that the first patient has been dosed in the Phase 2b...
Advertisements
Can-Fite Secures Australian Patent for Namodenoson in Liver and Pancreatic Cancer
Ramat Gan, Israel, July 14, 2026 Can-Fite BioPharma announced that the Australian Patent Office has allowed Patent Application No....
Vaxart Reports Positive 12-Month Phase 2b Safety Data
SOUTH SAN FRANCISCO, Calif., July 6, 2026 Vaxart, Inc. has announced positive topline 12-month safety results from the approximately...
Bial Discontinues Pariceract After Phase 2b ACTIVATE Trial Miss
PORTO, Portugal, June 9, 2026 Bial announced topline results from its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract)...
Structure Therapeutics Highlights Aleniglipron Phase 2b Success
SAN FRANCISCO, June 5, 2026 Structure Therapeutics Inc. announced the publication of detailed results from its Phase 2b ACCESS...
Ascletis Showcases Next-Generation Obesity Pipeline at ADA 2026
HONG KONG and NEW ORLEANS, Louisiana, June 8, 2026 Ascletis Pharma has strengthened its position in the highly competitive...
Advertisement
